Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.54 |
| ▸ | CNR1 | P21554 | 6/20 | 0.52 |
| ▸ | CNR2 | P34972 | 5/20 | 0.52 |
| ▸ | CASR | P41180 | 7/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4438711 | 0.86 | L3MBTL1 (0.50) | GLAL3MBTL1HCRTR1MEN1KMT2A | |
| SCHEMBL1838515 | 0.81 | HCRTR1 (0.61) | GLAL3MBTL1HCRTR1KMT2A | |
| SCHEMBL4435233 | 0.78 | KMT2A (0.62) | EPHX2L3MBTL1HCRTR1KMT2A | |
| SCHEMBL15339806 | 0.75 | CES2 (0.52) | EPHX2GLAMEN1KMT2A | |
| SCHEMBL9325544 | 0.75 | ALDH1A1 (0.60) | GLAL3MBTL1HCRTR1KMT2A | |
| SCHEMBL2725992 | 0.74 | CES2 (0.51) | GLAHCRTR1MEN1KMT2A | |
| SCHEMBL11667670 | 0.73 | ALDH1A1 (0.56) | GLAL3MBTL1HCRTR1MEN1KMT2A | |
| SCHEMBL4437536 | 0.73 | POLB (0.53) | GLAL3MBTL1MEN1KMT2A | |
| SCHEMBL15334134 | 0.73 | NPC1 (0.66) | GLAKMT2A | |
| SCHEMBL4436416 | 0.73 | MEN1 (0.53) | HCRTR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249128-B2 | Anti-cancer serine hydrolase inhibitory carbamates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249128-B2 | Anti-cancer serine hydrolase inhibitory carbamates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-02-02 | — | — | US | disclosed |
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2012058115-A2 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | CRAVATT BENJAMIN (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | AADAC, DDAH1, PRSS1 | MTNR1A 3983/4885MTNR1B 4217/4885CNR1 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.